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Abstract: A strict gluten-free diet (GFD) is the only currently available therapeutic 
treatment for patients with celiac disease, an autoimmune disorder of the small intestine 
associated with a permanent intolerance to gluten proteins. The complete elimination of 
gluten proteins contained in cereals from the diet is the key to celiac disease management. 
However, this generates numerous social and economic repercussions due to the ubiquity 
of gluten in foods. The research presented in this review focuses on the current status of 
alternative cereals and pseudocereals and their derivatives obtained by natural selection, 
breeding programs and transgenic or enzymatic technology, potential tolerated by celiac 
people. Finally, we describe several strategies for detoxification of dietary gluten. These 
included enzymatic cleavage of gliadin fragment by Prolyl endopeptidases (PEPs) from 
different organisms, degradation of toxic peptides by germinating cereal enzymes and 
transamidation of cereal flours. This information can be used to search for and develop 
cereals with the baking and nutritional qualities of toxic cereals, but which do not 
exacerbate this condition. 
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1. Introduction 
Celiac disease is a food intolerant related syndrome that, despite being under-diagnosed, is one of the 
most frequent chronic gastrointestinal disorders. It develops in genetically predisposed individuals in 
whom unidentified environmental factors (infections, changes in microbial flora, etc.) can trigger 
intolerance to gluten contained in wheat, barley, rye and oats [1,2]. Gluten is a complex mixture of 
proteins called prolamins. This protein fraction has specific name: wheat prolamins are termed gliadins 
and glutenins, barley prolamins are hordeins, rye prolamins are secalin and those from oats are avenins. 
A common characteristic of these proteins is the presence of multiple proline and glutamine  
residues, making them resistant to gastrointestinal digestion and more exposed to deamination by  
tissue transglutaminase. 
Several epitopes responsible for the toxicity of gluten have been identified based on their ability to 
stimulate proliferation of gluten-responsive T cells in celiac patient-derived small intestine biopsies. 
Considering only wheat, in the Immune Epitope Database (IEDB) [3] can be found 190 T-cell 
stimulatory epitopes related to celiac disease. Of these, 94 epitopes are located in α-gliadin genes, 74 in 
γ-gliadin genes, 12 in ω-gliadin genes, 8 in low molecular weight (LMW) glutenin genes, and 2 in high 
molecular weight (HMW) genes. 
The most accepted model for explaining the immunopathogenesis of celiac disease is the two-signal 
model, characterized by a first innate immune response and a subsequent secondary adaptive response, 
which will promote a histological lesion characterized by a massive intraepithelial infiltration of 
lymphocytes, crypt hyperplasia and villous atrophy [2]. The ingestion of these proteins leads to the 
inflammation, atrophy, and hyperplasia of the small-intestinal crypts of the celiac patient. However, this 
disease not only affects the gut, but it is a systemic disease that may cause injury to the skin, liver, 
joints, brain, heart, and other organs. 
Celiac disease goes in remission when the patients are put on a gluten-exclusion diet, and patients 
relapse when gluten is reintroduced into the diet [1,2]. Complying with a GFD is difficult and affects 
the patients’ quality of life, but a strict diet is critical to reduce morbidity and mortality [4]. 
Gluten has many special characteristics that favor its use in various food products. Because a large 
amount of gluten is generated during the manufacture of starch, it has a relatively low price. This may 
turn out to be problematic for people on a GFD, since gluten proteins may be found in unexpected 
sources such as meat, fish or milk products. This is the reason why alternative approaches to the GFD 
are actively sought [5], which include the search for and development of new cereals or gluten with no 
or low immunogenic content. In this article, we will review the current status of alternative cereals and 
their derivatives obtained by natural selection, breeding programs and transgenic or enzimatic 
technology, which may be potential tolerated by patients with celiac disease. 
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2. Natural Varieties of Cereal and Pseudocereals Suitable for Patients with Celiac Disease 
2.1. Wheat and Barley 
Cultivated wheat is genetically very complex due to its origin from ancestral diploid species  
through a process of natural hybridization and subsequent polyploidization. The two wheat species of 
agricultural importance, the pasta wheat, and the bread wheat, are tetraploid (two genomes, AABB) and 
hexaploid (three genomes, AABBDD), respectively (Figure 1). The tetraploids originated in nature 
through spontaneous hybridization of two diploid species, each donor genomes A and B, between 0.5 
and 2 million years ago. Bread wheat (AABBDD) originated in the fields, about 8000 years ago, through 
spontaneous hybridization between durum wheat (AABB) and Aegilops tauschii, the diploid donor of 
the D genome (Figure 1). 
One species of wheat, Triticum aestivum, is predominantly used in the modern industrialized world, 
due to its increased protein production as well as its hardiness in colder climates. It has also been 
determined that the proteins that are the most immunogenic for celiac disease reside in the gliadin 
fraction of T. aestivum. However, there are almost 20 other species of wheat that are either not being 
cultivated by modern societies or are cultivated in select regions of the world [6]. With such a large 
number of wheat species available, a significant amount of research has been focused on the 
exploration of different species and cultivars of wheat as an alternative to a strict GFD for celiac 
patients [7]. 
Figure 1. Diagram showing the evolutionary relationships among species of wheat and 
related species of Aegilops. The dotted line separates the wild and domesticated species of 
wheat. Ancestral or unknown species are surrounded by a double dashed rectangle. Ploidy 
level and the number of chromosomes are indicated. Nomenclature according to van 
Slageren [8]. 
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Attempts have been made to quantify the toxicity of a range of bread wheat and pasta wheat 
varieties and of species that contain only one of the three genomes of bread wheat [9,10]. Using 
specific T-cell clones and monoclonal antibodies, the results demonstrated that large quantitative 
differences exist in the presence of toxic gluten peptides, with some cultivars completely lacking 
particular harmful peptides [11]. Diploid wheat species are among the suitable candidates for their low 
capability to activate intestinal T cell responses in celiac patients [11,12]. Compared with tetraploid 
and hexaploid wheat, commonly used in the making of bread and pasta, the ancient diploid  
Triticum monococcum ssp. monococcum wheat showed a marked reduction, or even a lack, of toxicity 
in vitro cellular assays [13,14]. Gianfrani et al. [15] compared the immunological properties of 2 lines 
of diploid monococcum wheat, Monlis and ID331, with those of T. aestivum. They found that both 
lines activate celiac T cell response. However, ID331 was less effective to activate the innate immune 
pathways. The reduced ability of some diploid wheat lines to in vitro activate the innate immune 
response in celiac mucosa could render these cultivars less active in inducing celiac disease. However, 
more analyses are required to explore their potential use as new dietary opportunities for celiac patients. 
Some approaches were performed to remove celiac toxic proteins in barley. Double-null hybrid 
plants, largely devoid of both B- and C-hordeins, were produced by conventional crossing [16]. Barley 
is a diploid and unlike the situation in bread wheat, the genetics of hordeins are relatively 
straightforward. There are four protein families of hordeins: B-, C-, D- and γ-hordeins, with the B- and 
C-hordeins together accounting for over 90% of barley hordeins. Isolation of hordein double-null 
barley lines from hybrids of Risø 56 and Risø 1508 has produced a line which does not accumulate  
B- or C-hordein and only has 3% of wild type hordein along with a 20-fold reduction in reactivity in 
T-cell assays [16,17]. In addition, studies carried out demonstrated that some malting  
lines (Hordeum vulgare) were less immunogenic compared with wild lines (Hordeum chilense) [18]. 
These findings could raise the prospect of breeding barley species with low levels of harmful gluten, and 
the attractive goal of developing non-toxic barley cultivars with a potential use in the manufacture of 
beverages as consumed worldwide as are the beers. However, nothing is known about the variability in 
celiac toxicity of other species or varieties of toxic cereals such as rye. 
2.2. Oats 
Cultivated oats are hexaploid cereals belonging to the genus Avena L., which is found worldwide in 
almost all agricultural environments [19]. Recently, oats have been receiving increasing interest as 
human food, mainly because the cereal could be suitable for consumptions by celiac patients. Several 
varieties of oats are available. It is a rich source of protein, contains a number of important minerals, 
lipids, β-glucan, a mixed-linkage polysaccharide, which forms an important part of oat dietary fiber, 
and also contains various other phytoconstituents like avenanthramides, an indole alkaloid-gramine, 
flavonoids, flavonolignans, triterpenoid saponins, sterols, and tocols. Traditionally oats have been in 
use since long and are considered as stimulant, antispasmodic, antitumor, diuretic, and neurotonic. Oat 
possesses different pharmacological activities like antioxidant, anti-inflammatory, antidiabetic, 
anticholesterolaemic, etc. [20]. 
The presence of oats in a GFD is still a subject of controversial. Oats differ from other cereals in 
their prolamin content. The percentage of proline and glutamine (amino acids abundant in toxic 
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regions) in avenin is lower than in other toxic cereals. Some clinical researchers state that patients with 
celiac disease tolerate oats without signs of intestinal inflammation [21]. According to the Codex 
Alimentarius for food for special dietary use for persons intolerant to gluten, CODEX STAN118-1979 
(revised 2008, [22]), oats can be tolerated by most but not all people who are intolerant to gluten. 
Moreover, according to the Commission Regulation (EC) No 41/2009 [23] concerning the composition 
and labeling of foodstuffs suitable for people intolerant to gluten, a major concern is the contamination 
of oats with wheat, rye or barley that can occur during grain harvesting, transport, storage and 
processing. Therefore, the risk of gluten contamination in products containing oats should be taken 
into consideration with regard to labeling of those products. In contrast, other studies confirmed the 
toxicity of oats in certain types of patients with celiac disease. Arentz-Hansen et al. [24] described the 
intestinal deterioration suffered by some patients with celiac disease following the consumption of oats 
while on a GFD. Avenin can trigger an immunological response in these patients similar to the 
response produced by the gluten of wheat, rye or barley. The monitoring of 19 adult patients with 
celiac disease who consumed 50 g/day of oats over 12 weeks showed that one of the subjects was 
sensitive to oats. Therefore, it is critical to clarify either qualitatively or quantitatively the potential 
immunotoxicity of oats to patients with celiac disease [21,24]. 
Comparison of the different studies are complicated by the different study designs, the different 
conditions used in the testing, the number of subjects included in each study and the reporting of the 
purity control of the oat material used in the clinical trials. Another relevant factor in different designs 
is the absence of information on the oat variety used. Silano et al. [25] investigated the immunogenic 
effect of avenins from four oat cultivars using peripheral lymphocytes from patients with CD. All the 
varieties of oats tested (Lampton, Astra, Ava, and Nave) by these investigators were immunogenic 
with differences in their capacity to induce a response. However, other study confirmed that  
Avena genziana and Avena potenza do not display in vitro activities related to CD pathogenesis [26]. 
The utility of the G12 antibody to identify potentially toxic oat varieties for celiac patients has been 
reported [27]. This finding allowed classification of oat varieties into three groups based in their 
degree of affinity for the G12 antibody: a highly recognized group, one of moderate recognition, and 
one with no reactivity [27]. These results were confirmed by MALDI-TOF, SDS-PAGE and western 
blot by showing that the number, relative intensity of the peaks and protein profile obtained for the 
nine oat varieties differ from one another. The potentially immunotoxicity of the different types of oats 
was determined by T cell proliferation and interferon γ release. The reactivity that T-cells isolated from 
celiac patients exhibited with three oat varieties (one from each of the classified groups) correlated 
directly with the moAb G12 reactivity. The diversity observed in the reactivity to the different oat 
cultivars suggests variations in the avenin composition, and therefore in the amount of immunotoxic 
epitopes similar to the 33-mer present in these varieties. This gives a rational explanation for why only 
some oats trigger an immunological response. 
In comparison with wheat gliadins, the avenins have been little studied, and the number of full 
avenin genes present at the moment in the databases is limited and from few genotypes, so that the 
variability of avenin genes in oats is not well represented. It has recent been known that, like wheat, 
oat grains have both monomeric and polymeric avenins [28]. A direct correlation between the 
immunogenicity of the different varieties of oats and the presence of the specific peptides with a 
higher/lower potential immunotoxicity has been found, that could explain why certain varieties of oats 
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are toxic for celiac patients and other not [28]. The incorporation of some varieties of oats in food 
products not only may improve the nutritional quality but also may provide a treatment for various 
illnesses and would be welcomed by patients with celiac disease. 
2.3. Other Cereals and Pseudocereals 
It is well-known that the high nutritional value of gluten containing cereals and the viscoelastic 
network generated by the gluten that enables an excellent aerated structure in food products. In contrast, 
cereal based gluten-free products can be rich in carbohydrates and fats, and they have deficiencies in 
macronutrients and micronutrients. In consequence, long time adherence to GFD could induce nutrients 
deficiencies. Different proteins have been proposed as alternative for both playing the polymer role and 
increasing the nutritional value of gluten-free products. The incorporation of other ingredients/nutrients 
like 3-omega lipids, specific proteins, etc. is an alternative to improve the nutritional composition of 
gluten-free products. 
Figure 2. Taxonomic relation of known non-toxic cereals, minor cereals and pseudocereals 
in the context of celiac disease. 
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It is noteworthy that many grains (members of the grass family) that are closely related to wheat, rye 
and barley are considered toxic based on taxonomy. Furthermore, some studies focused on the protein 
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homology in grains have supported molecular evidences [28,29]. However, member belonging to other 
tribes that appear to be related to corn, are considered safe (Figure 2) and can serve as substitutes and 
provide flours for cooking and baking for celiac and gluten-sensitive individuals. There are protein 
studies in support of this conclusion, although the studies are not sufficiently complete to provide more 
than guidance. 
Non-gluten-containing sources frequently used in product formulation include cereals (rice, corn and 
sorghum), minor cereals (fonio, teff, millet, and job’s tears) and pseudocereals (buckwheat, quinoa and 
amaranth). As the environmental conditions for growing these grains are variable, availability of regular 
supplies is not always assured. 
2.3.1. Rice, Maize and Sorghum 
Rice is the seed of the monocot plant of the genus Oryza and of the grass family Poaceae (formally 
Graminae), which includes twenty wild species and two cultivated ones, Oryza sativa (Asian rice) and 
Oryza glaberrima (African rice). Rice is one of the most important foods in the human diet and extended 
cereal crop. Rice is mainly consumed as white grain, but in the last decade, dozens of products 
containing rice as an ingredient have appeared on the food market [30]. There has been a notable 
increase in the use of rice flour in the formulation of gluten-free products for their hypoallergenic 
qualities or hypoallergenicity in spite of it is necessary to use a hydrocolloid, emulsifier, enzyme or 
protein to confer viscoelastic properties [30,31]. 
Maize (Zea mays subsp. mays L), also known as corn, is considered as a safe cereal for celiac patients. 
It is used as alternative to elaborate gluten-free foodstuffs. Some celiac patients considered refractory to 
the treatment with a GFD improved when a corn-free diet was prescribed [32]. However, some studies 
have showed the certain maize prolamins (zeins) contain amino acid sequences that resemble the wheat 
gluten immunodominant peptides and their integrity after gastrointestinal proteolysis is unknown [33]. 
Darewickz et al. [34] detected amino acid sequences with a high degree of identity to the celiac-toxic 
peptides in maize prolamins (zeins). This could be because the zeins, like other storage proteins, have its 
origin in the alpha-amylase inhibitors [35]. 
Sorghum (genus of numerous species of grasses) is a drought-and heat-tolerant cereal grain that 
grows in semiarid conditions. Whereas sorghum traditionally has been used primarily as animal feed in 
western countries, nearly 40% of the world sorghum production is used for human food in Africa and 
India. Immunological studies and in vitro and in vivo challenges of sorghum food products have 
supported that sorghum might provide a good basis for gluten-free foods [36]. In a recent study,  
Pontieri et al. [37] by using in silico approaches and biochemical/immunochemical experiments have 
demonstrated that sorghum can be definitively considered safe for consumption by people with celiac 
disease for the absence of toxic gliadin-like peptides. 
2.3.2. Minor Cereals 
Minor cereals, so called because they are less common and are only grown in a few small regions of 
the world, included fonio, teff, millet, teosinte and Job’s tears [38]. 
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Fonio (Digitaria exilis) is a typically cereal in Sudan or Ethiopia where it is considered to be the 
tastiest of all cereals [38]. Fonio can survive in poor soil conditions such as sandy and acidic soils and its 
composition is similar to that of other millets: limited in lysine, but rich in methionine [39]. 
Teff (Eragrostis tef) is the smallest of all grains in the world and it is classified on the basis of seed 
color, ranging from milky white to almost black. Teff is a cereal traditionally grown in Ethiopia and used 
to make injera or flat bread. 
Millet refers to a number of different species of the Pennisetum genus, all of which are small-grained, 
annual cereal grasses. The most important type for food consumption is pearl millet that is similar in 
texture to rice flour [38]. 
Job’s tears (Coix lacryma-jobi), also known as Chinese Pearl Barley, is a type of millet wild tropical 
Asian grass related to maize. Job’s tears is naturally gluten-free, but similar to other grains it may be 
contaminated during processing by comingling with gluten grains such as wheat. It is used as a source of 
food and drinks. 
2.3.3. Pseudocereals 
Pseudocereals are non-grasses plants which grains are used in the same way that true cereals. 
Pseudocereals seeds can be ground into flour and then to produce derived products like bread and pasta. 
Recently, the use of pseudocereals producing small grain-like seeds like amaranthus and quinoa 
(Amaranthaceae family), belonging to dicotyledons (Magnoliopsida class), have been considered for the 
preparation of gluten-free food products because the lack toxic seed proteins and have high nutritional 
value [40]. However, the believed lack of toxicity for most of these pseudocereals was based on their 
taxonomical classification rather than a direct evaluation of their inmunostimulator activity. 
Several studies affirmed that amaranth and quinoa have high quality protein in terms of digestibility, 
efficiency ratio and nutrition balance, almost equivalent to that of milk protein casein [41,42]. 
Additionally, these pseudocereals are also rich in polyunsaturated fatty acids (high linolenic:linoleic acid 
ratio) and bioactive compounds such as γ- and β-tocopherol, polyphenols and flavonoids. 
The genus Amaranthus L. contains more than 60 species; A. caudatus, A. cruentus and  
A. hypochondriacus are those most used for human nutrition. Amaranth proteins consist mainly of 
albumins and globulins, where prolamins, the toxic proteins for celiac patients, are very scarce. The 
essential amino acids content is high in amaranth seeds and the amino acid composition is better 
balanced than in most cereals. It is a good source of riboflavin, vitamin E, calcium, magnesium and 
irons, among minerals [40]. Studies focused on investigate from the molecular point of view the protein 
patterns from different amaranth cultivars to verify their suitability for the diet of subjects suffering from 
celiac disease, suggested that amaranth may be safely included in a GFD. However, controlled clinical 
studies are necessary to confirm the results and support the inclusion in the celiac’s diet [40]. 
Quinoa (Chenopodium quinoa) is an Andean grain that has been consumed for thousands of years in 
South America and was a staple of the Incas. There are hundreds of varieties of quinoa, ranging in color 
from white to red and purple to black [38]. Quinoa has a high biological value (83%) because of its high 
concentration of proteins (<23%), providing all of the essential amino acids [43–45]. Quinoa has 
important applications in the food and pharmaceutical industries. Due to its excellent nutritional value 
and a potential for production in various climates, quinoa has been classified as one of the humanity’s 
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most promising crops [46]. Several studies to examine the suitability of quinoa for patients with celiac 
disease have been carried out in last years and concluded that quinoa could be a safe addition to a GFD. 
However, 2 cultivars had celiac-toxic epitopes that could activate the adaptive and innate immune 
responses in some patients with celiac disease [45]. A complete in vivo characterization of  
quinoa protein reactivity is needed to recommend their consumption by patients with celiac  
disease [45,47,48]. 
Buckwheat (Fagopyrum spp.) is botanically classified as a fruit and it is thought to have originated in 
China. It can be consumed as grains or as flour. The toasted grains are known as Kasha. Buckwheat is a 
highly nutritious pseudocereal known as a dietary source of protein with favorable amino acid 
composition and vitamins [49], starch, and dietary fiber [50], essential minerals (Steadman and others 
2001), and trace elements [51]. Two species of buckwheat are cultivated for food consumption, 
Fagopyrum esculentum or common buckwheat and Fagopyrum tartaricum or tartary buckwheat [52]. 
Common buckwheat is primarily consumed in Asian countries. However, consumption in western 
countries including the United States is increasing due to it is the substitute for wheat flour for 
gluten-sensitive patients and as a health food because of its nutrient content [53,54]. It has been reported 
cases of buckwheat allergy in Japan, Korea and Europe [55]. 
2.3.4. Other Cereals 
An alternative grain that may potentially be considered for celiac patients is glabrous canary seed 
(Phalaris canarienses L.) that belongs to the Poaceae (Gramineae) family. In a recent study carried out 
by Boye et al. [30] confirmed that glabrous canary seeds were a good alternative gluten-free cereal and 
reported three techniques able to be used to support gluten-free labeling of products that contain it. 
3. Modified Harmless Cereal Varieties 
3.1. Gluten Detoxification by Biotechnological Methods 
The use of genetic engineering to down-regulate gene expression by RNA interference (RNAi) 
technology [56] is now routine in many crops, including wheat, and is therefore an attractive opportunity 
for reducing the immunotoxic components of gluten and, hence the incidence of gluten-related allergies 
and intolerance in wheat. Several groups have taken advantage of the possibilities that the RNAi 
technology offers for the silencing of multigene families, and they have addressed the down-regulation 
of more than one group of gliadins and/or glutenins. 
This technology was applied to down-regulated the expression of α-gliadins [57], γ-gliadins [58,59], 
ω-gliadins [60], all gliadins [61], and gliadins and LMW-GS [62] in bread wheat. These examples show 
the usefulness of RNAi to silence specific genes corresponding to gluten proteins, which are the known 
sources of immunogenic epitopes. However, only transgenic lines deficient in γ-gliadins [58] and in all 
three gliadin fractions [61] have been tested by monoclonal antibodies and T-cell assays for these 
transgenic lines to be used in foodstuff tolerated by many patients with celiac disease or other 
gluten-related pathologies. 
Results reported by Gil-Humanes et al. [58] and Piston et al. [59] used two hpRNA construct to 
silence the γ-gliadins in two genotypes of the bread wheat cv ―Bobwhite‖. They reported 18 transgenic 
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lines with reduction of the γ-gliadin fraction, from 65 to 97% depending of the transgenic line [59]. The 
reduction of γ-gliadins was also accompanied by an increase in other storage proteins, in particular, the 
ω- and α-gliadins, and the HMW-GS and LMW-GS. However, the total gliadin content did not show 
significant differences in the transgenic lines relative to the wild types. Later, two hpRNA constructs 
designed using a chimeric sequence encompassing highly conserved genes among α-, ω-, and γ-gliadins 
were reported [61]. They showed that the chimeric fragment was able to effectively down-regulate the 
expression of genes from all three gliadin groups. The gliadin composition of the transgenic lines, 
determined by RP-HPLC, showed a significant reduction of the gliadin content in all of the transgenic 
lines, ranging from 70% to 88%. Overall, the gluten proteins were decreased up to 56% while the 
non-gluten proteins albumins and globulins were increased in some transgenic lines [63], as 
consequence, the total nitrogen content of the grain was not significantly affected. 
These lines hold good potential to be used in foodstuff tolerated by many patients with celiac disease 
or other gluten-related pathologies. The competitive ELISA system based on monoclonal antibody [64] 
is a good assay for quantifying the amount of gluten in foods [65]. For transgenic lines with γ-gliadins 
silenced [58,61], gliadin content (ppm) did not decrease significantly but increased for some lines as 
consequence of the compensatory effects with other gliadins, specifically α- and ω-gliadins. However, 
when gluten proteins from transgenic lines, deficient in all three groups of gliadins, were tested by the 
monoclonal antibody, there was a significant reduction of the gliadin content in all of the transgenic 
lines, with the average reduction of 92% and a range between 90% and 98% [61]. Total gluten proteins 
were extracted for T-cell assays, treated with recombinant human TG2, and tested in serial dilution for 
stimulation of DQ2- and DQ8-restricted T-cell clones of celiac patients [61]. The transgenic lines 
deficient only in γ-gliadins retained high amounts of α- and ω-gliadins, and the DQ2-γ-VII–specific 
T-cell clone gave strong response to the total gluten extract from those lines [61]. In contrast, a 
pronounced reduction in proliferative responses was seen in some transgenic lines deficient in all three 
gliadin fractions. There was about a 2-log reduction in the expression of the DQ2-α-II epitope in these 
transgenic lines. The responses of the T-cell clones specific for the other epitopes (DQ2-γ-VII, DQ8-α-I, 
and DQ8-γ-I) were at or below detection level for the highest concentration of gluten protein tested. 
They concluded that transgenic lines containing around 30% of ω-gliadin, 10% of α-gliadin, and only 
1% of γ-gliadin compared with their wild-type control, were particularly inefficient to stimulate the 
celiac disease lesion-derived T cells [61]. 
One important question is how quality is affected by the silencing of gliadins, or other gluten proteins. 
The rheological and gluten properties, and baking quality of wheat lines with the α-gliadins 
down-regulated were reported [66]. They showed that the deficiency of α-gliadins did not substantially 
affect the baking performance of wheat flour, although breads made using flour from lines with 
α-gliadins silenced had lower volumes (−11%) compared to that of wild type breads. The mixing 
properties of 18 transgenic lines with the γ-gliadins down-regulated were determined by using the 
mixograph and sodium dodecyl sulfate sedimentation (SDSS) test [59]. They concluded that the 
reduction of γ-gliadins seems not to have a direct effect on the mixing and bread-making properties of 
wheat dough, but the compensatory effect on the synthesis of the other prolamins can provide stronger 
doughs with improved overmixing resistance. Although gliadins are not the main component affecting 
the bread-making quality of wheat, it is unknown the effect that the silencing of all three groups of 
gliadins [61], or gliadins and LMW-GS [62] will have on wheat quality. Preliminary results  
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reported [61] based on SDSS test, showed that most of transgenic lines with ω-, γ- and α-gliadins down 
regulated had SDSS volumes comparable with those of wild types, and five lines had SDSS volume 
values significantly lower than wild types. However, SDSS volumes of these five lines were still 
comparable with those of the medium-quality bread wheat. The addition of non-toxic oat flour [67], or 
other flours from gluten-free cereals or pseudocereals, such as sorghum, buckwheat and quinoa [37,68], 
might compensate the lack of gliadins, enhancing the quality of the new wheat varieties. 
3.2. Gluten Detoxification by Enzymatic Methods 
Food proteins are usually degraded into small peptides and amino acids by gastric, pancreatic and 
brushborder enzymes. However, gluten proteins are highly resistant to complete proteolytic digestion 
due to their high proline and glutamine content. Since the pioneering experiments carried out by Frazer 
et al. [69], who determined that celiac-toxic proteins could be partially hydrolyzed by gastrointestinal 
enzymes without loss toxicity, several strategies have been considered for detoxification of dietary 
gluten. Some of these strategies have been based on treatment with special peptidases that hydrolyze 
toxic protein and peptides to nontoxic fragments. 
The beginning for the enzymatic strategies was the findings that the toxicity was abolished by 
complete acidic hydrolysis [70]. However, researches about gluten detoxification were not developed 
until 21st century. The approaches included enzymatic cleavage of gliadin fragment by PEP from 
different organisms, degradation of toxic peptides by germinating cereal enzymes and transamidation of 
cereal flours [5]. 
3.2.1. Prolyl Endopeptidases 
Shan et al. [71] were the first in propose that PEPs could catalyze breakdown of gluten peptides and 
thereby diminish its toxic effects. This hypothesis was based on that the abundance and location of 
proline residues is a crucial factor for the gastrointestinal resistance, and the unique ability of these 
enzymes to hydrolyze the peptide bond on the carboxyl side of a proline residue. Since then, further 
studies have shown that the fermentation of wheat, rye and barley flours with selected peptidases cause a 
significant decrease of gluten toxicity. The PEPs are widely distributed in bacteria, fungi, animals and 
plants, but it is known that lactic acid bacteria (lactobacilli) have a very complex peptidase system [72]. 
Lactobacilli species isolated from sourdoughs have been screened with respect to gluten degradation, 
finding that a pool of peptidases is needed to degraded α-gliadin fragments [73]. Studies based on use 
lactobacillus as microbial inoculum during fermentation of flour mixture has shown a potential ability to 
hydrolyze wheat prolamins by in vitro and in vivo assays [74]. Despite that, the gluten concentration 
remains high, therefore studies based on more complex formulas were developed. Recently, the 
combination of lactobacilli and fungal peptidases has been selected to eliminate the toxicity of wheat 
flour during long-time fermentation. Thus, food processing by selected proteases opens new 
perspectives toward an efficient approach to eliminate gluten toxicity. 
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3.2.2. Germinating Cereals 
The role of the proline- and glutamine-rich storage proteins of cereals is to supply the embryo with 
nitrogen and amino acids during the first period of seedling development. Therefore, it is likely that 
endogenous cereal proteases synthesized during germination would be capable of extensively 
hydrolyzing these proteins [75]. Given evidences about this capacity, the use of proteases from 
germinating wheat seeds was proposed to create safe cereal products for celiac patients [76,77]. The 
analysis of protein content by RP-HPLC during kernels germination of wheat, rye and barley 
demonstrated a remarkable degradation of prolamins. In further experiments, protease extracts from 
these germinated cereals cleave peptides rapidly into non-toxic fragments with less than nine amino 
acids [75]. Comparative studies of proteases efficacy from different cereals by in vitro models have 
revealed that barley enzymes were superior in diminish the toxicity of gliadin and secalin, but there were 
only minor differences between the three enzyme mixtures (oats, wheat and barley) [78]. On the other 
hand, it should be pointed out that germinating cereal proteases have distinct advantages in comparison 
to bacterial and fungal peptidases. These enzymes derive from a naturally safe food source being 
excellent alternatives to recombinant proteases, which might not be accepted by many celiac patients. 
Indeed, the production of germinated cereals, just like the extraction of highly active proteases, is simple 
and well-established technological process [75]. Altogether, these enzymes from germinating cereals 
might be utilized in food processing to develop high quality food safe for celiac patients. 
3.2.3. Transamidation 
The enzyme transglutaminase (TG) catalyzes two classes of reactions, transamidation and 
deamidation. The first one transforms the primary γ-carboxamide group to a secondary one, and in the 
second reaction, the glutaminyl residue is converted to a glutamyl residue [79]. Tissue transglutaminase 
2 (tTG) has been describe as one of the key factor in the immunopathogenesis of celiac disease because 
of gluten peptides increase their immunogenicity due to the deamidation [80]. Considering that only the 
transamidation might be use for gluten detoxification, several studies have been focused to know the 
ratio between these two reactions [81,82]. It seems that the ratio can vary considerably depending on 
different factors like the presence of primary amines, the peptide sequence as well as enzyme 
concentration. In general terms, it has been found highest rate of deamidation in tTG, however, the few 
studies carry out with TGs from other origins have shown a considerably lower deamidation versus 
transamidation activity in microbial TG (mTG) [83,84]. Based on that, Gianfrani et al. [85] treated 
wheat flour with mTG and lysine methyl ester to abolish gluten activity, detecting the decrease of the 
activity mediated by T-cell. Thus, they suggested a food-grade enzyme and an appropriate amine donor 
to block the T cell-mediated gliadin activity [85]. Recently, Mazzarella et al. [86] has shown in a 
randomized single blinded trial that transamidated gluten reduced the number of clinical relapses in 
challenged patients with no changes of baseline values for serological/mucosal celiac markers and an 
unaltered kidney function. Other application has been use the mTG from S. mobaraensis to detoxify 
cereal-based beverages since the beer treatment with mTG will lead to crosslinking of residual gluten 
peptide. If that aggregate exceeds a certain MW, they lose their solubility and can be removed from the 
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beer resulting in beverages with gluten content below 20 mg/kg [87]. Therefore, although mTG is not 
able to degrade gluten, it could be used to immunodetoxify gluten. 
4. Conclusions 
Currently the only treatment for celiac disease is a lifelong GFD. However, adherence to the GFD is 
not easy, due to the ubiquitous nature of gluten, cross-contamination of foods and social constraints. 
While many patients are content with their GFD, others would welcome alternative treatments and/or 
food products that would allow more flexibility. 
Here, we review the status of potential alternative cereals and pseudocereals and their derivatives 
under consideration for celiac disease. Diploid wheat species appear to be among the suitable 
candidates for their low capability to activate intestinal T cell responses in celiac patients. Compared 
with tetraploid and hexaploid wheats commonly used in the making of bread and pasta, the ancient 
diploid Triticum monococcum ssp. monococcum wheat showed a marked reduction of toxicity in vitro 
assays. Moreover, the use of genetic engineering to down-regulate gene expression by RNAi 
technology represents an attractive opportunity for reducing the immunotoxic components of wheat. 
Simultaneous silencing of the full complement of gliadins results effective for the reduction of T-cell 
epitopes in celiac disease. 
Several studies have been demonstrated that oat immunogenicity for patients with celiac disease 
varies according to the cultivars. The incorporation of some varieties of oats in food products not only 
may improve the nutritional quality, but may provide a treatment for various illnesses and would be 
welcomed by patients with celiac disease. 
Non-gluten-containing sources frequently used in product formulation include cereals (rice, corn and 
sorghum), minor cereals (fonio, teff, millet, and job’s tears) and pseudocereals (buckwheat, quinoa and 
amaranth). However, new studies seem to show that certain cereals and pseudocereals such as corn and 
quinoa, traditionally considered safe for celiac patients, could activate the immune response in some 
celiac patients. 
More recently, studies have been showed several strategies for detoxification of dietary gluten 
based on treatment with special peptidases that hydrolyze toxic protein and peptides to nontoxic 
fragments. These included enzymatic cleavage of gliadin fragment by PEPs from different organisms, 
degradation of toxic peptides by germinating cereal enzymes and transamidation of cereal flours. Food 
processing by selected proteases opens new perspectives toward an efficient approach to eliminate 
gluten toxicity, which could allow the development of foods with reduced or absent levels of gluten. 
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